Litigation Details for Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-12-07 |
| Court | District Court, D. Delaware | Date Terminated | 2021-09-08 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 6,956,041; 7,091,208; 7,265,221; 7,301,023; 9,937,181 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pfizer Inc. v. Teva Pharmaceuticals USA, Inc.
Biologic Drugs cited in Pfizer Inc. v. Teva Pharmaceuticals USA, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-12-06 | 1 | Xeljanz XR that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December 8, 2020); 7,091,208 (… infringement of United States Patent No. 9,937,181 (the “’181 patent”). 2. This action …181 patent as March 14, 2034. 18. The Orange Book also lists four additional patents for …). The ’181 Patent 19. On April 10, 2018, the USPTO issued the ’181 patent, titled “Tofacitinib…Forms.” The ’181 patent is duly and legally assigned to Pfizer. A copy of the ’181 patent is attached hereto | External link to document | |
| 2021-01-19 | 102 | Notice of Service | Fleckenstein, Pharm.D., Regarding Validity of U.S. Patent No. 9,937,181; and (3) Responsive Expert Report of Leah…Appel, Ph.D., Regarding Validity of U.S. Patent No. 9,937,181 filed by C.P. Pharmaceuticals International… 8 September 2021 1:18-cv-01940 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
